Tag: GlobeNewswire

• In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21

• SD is most prevalent type of chronic inducible urticaria (CIndU)²; more than 50% of patients remain symptomatic despite taking H1 antihistamines3

• Rhapsido showed safety profile in SD consistent with CSU, with no routine lab monitoring required1

• Approval builds on established role of Rhapsido in CSU and highlights potential of BTK inhibition across immune-mediated diseases

Basel, October 7, 2026 – Novartis announced today that the U.S. Food and Drug Administration (FDA) approved Rhapsido^® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. The approval represents an important advancement for people whose chronic hives and itch can be triggered by everyday skin friction, scratching, or rubbing.

Over 90% of adults with chronic hives experience chronic spontaneous urticaria (CSU) or SD. Rhapsido is the only prescription treatment with approved uses in both CSU and SD when antihistamines alone do not control symptoms.⁴

“SD is a chronic, debilitating condition with historically limited treatment options,” said Giselle Mosnaim, MD, MS, an Allergist and Immunologist at Endeavor Health, Clinical Professor at the University of Chicago Pritzker School of Medicine, and lead RemIND trial investigator. “Remibrutinib offers, for the first time, an approach to treatment specifically for SD patients who remain inadequately controlled with H1 antihistamines alone, representing a meaningful step forward for this population.”

The FDA approval is based on data from the SD cohort of the Phase III RemIND clinical trial in patients who remained symptomatic on second-generation H1 antihistamines. Rhapsido demonstrated higher rates of complete response from hives compared to placebo as measured by the Total Fric Score.¹ At Week 12, significantly more patients treated with Rhapsido versus placebo achieved complete response from hives (29.3% vs 14.0% with placebo; p=0.0229), with responses seen as early as Week 2.¹

In clinical trials up to Week 24, Rhapsido demonstrated a consistent safety profile in SD and CSU.¹ The most common adverse events (incidence ≥3%) were nasal congestion, sore throat, and runny nose (nasopharyngitis), bleeding, headache, nausea, and abdominal pain.¹

“As both a patient and an advocate, I know how important it is for SD to be recognized and understood,” said Kristen Willard, Executive Director of We CU, a global community supporting people with chronic urticaria (CU) through awareness, advocacy, education, and research. “For the SD community, the approval of remibrutinib represents important progress. People living with this condition deserve treatment options developed specifically for this condition, and we are hopeful about what this milestone means for the community.”

Expanding Rhapsido indications across chronic hives
With the FDA approval in SD, Rhapsido is now the only treatment indicated for the two most common forms of chronic hives: CSU and SD. Beyond SD, the RemIND study also evaluated remibrutinib in additional forms of CIndU, including cold urticaria (ColdU) and cholinergic urticaria (CholU). The company plans to submit the full RemIND dataset to health authorities globally, where appropriate.

“For people living with SD, seemingly routine contact with the skin can trigger hives and itch,” said Lindsey Finklea, MD, a Dermatologist and Adjunct Professor at the University of Texas at San Antonio and RemIND trial investigator. “Having the first FDA-approved medicine specifically for SD marks an important change in how clinicians can approach care and offers renewed hope for patients whose symptoms are not adequately controlled by H1 antihistamines.”

Remibrutinib continues to be studied in other immune-mediated conditions, including hidradenitis suppurativa (HS) and food allergy. In addition, Novartis recently announced positive topline results from its Phase III REMODEL-1/-2 trials in relapsing multiple sclerosis (RMS), showing that remibrutinib demonstrated a clinically meaningful reduction in annualized relapse rates and a clinically meaningful delay in disability progression vs teriflunomide with a favorable safety profile and no liver safety signals, consistent with CSU.⁵

“Today’s approval marks an important milestone for people living with SD and builds on the first FDA-approved indication for Rhapsido in CSU just over a year ago,” said Victor Bultó, President, US, Novartis. “With Rhapsido now approved for the two most common forms of chronic hives, more people may have the opportunity to find relief from persistent itch, regain confidence in their daily lives, and focus less on their symptoms and more on the moments that matter. We are proud to advance the science of BTK inhibition as we work to bring new treatment options to patients with unmet needs across immunology and beyond.”

About Rhapsido^® (remibrutinib)
Rhapsido^® (remibrutinib) is a highly selective, oral Bruton’s tyrosine kinase inhibitor (BTKi) that blocks the BTK pathway involved in the release of histamine, a key driver of hives (wheals) and swelling.¹ In the U.S., Rhapsido is an approved treatment for adults with chronic spontaneous urticaria (CSU) and symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. Rhapsido is also approved in the EU, UK, and China for the treatment of adults with CSU inadequately controlled by H1 antihistamines. Remibrutinib continues to be studied in other immune-mediated conditions, including hidradenitis suppurativa (HS) and food allergy, as well as multiple sclerosis (MS).

About Novartis Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with immune-mediated diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. Rhapsido. Prescribing information. Novartis Pharmaceuticals Corp.
2. Pozderac I, et al. Chronic inducible urticaria: classification and prominent features of physical and non-physical types. Acta Dermatovenerol Alp Pannonica Adriat. 2020;29(3):141–8
3. Bernstein JA, Winders TA, McCarthy J, et al. The Urticaria Voices study: Experiences and unmet needs of patients with chronic inducible urticaria (CIndU). Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025; 2025. Abstract 000934. Oral presentation.
4. Data on file. Novartis Pharmaceuticals Corp. August 2026.
5. Data on file. Novartis to present late-breaking data at MSToronto2026. Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials. https://www.novartis.com/news/media-releases/novartis-remibrutinib-high-efficacy-oral-btk-inhibitor-significantly-reduces-relapse-rates-and-shows-favorable-safety-profile-phase-iii-rms-trials. Accessed October 7, 2026. 

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

Series	RIKB 29 0416	RIKB 38 0215
ISIN	IS0000039121	IS0000037265
Maturity Date	04/16/2029	02/15/2038
Auction Date	10/09/2026	10/09/2026
Settlement Date	10/14/2026	10/14/2026
10% addition	10/13/2026	10/13/2026
Buyback issue	RIKB 27 0415
Buyback price (clean)	99.8100

On the Auction Date, between 10:30 a.m. and 11:00 a.m., the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%. The Treasury bonds will be delivered in electronic form on the Settlement Date.

Payment for the bonds can be made in cash or with the Buyback issue at the Buyback price.

Payment in cash for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date. If payment is made with the Buyback issue, a notification of the amount must be received no later than by 14:00 on the Auction Date. In that case, the value of the Buyback bond is determined by the Buyback price plus accrued interest (i.e. dirty price).

No fee is paid in relation to the purchase of RIKB 27 0415.

Further reference is made to the description of the Treasury bond and the General Terms of Auction of Treasury Bonds.

For additional information please contact Magnús Freyr Hrafnsson, Government Debt Management, at +354 569 9679.

KALMAR CORPORATION, TRADE PRESS RELEASE, 7 OCTOBER 2026 AT 18:30 (EEST)

Kalmar and Port of Halmstad continue partnership with the signing of a Kalmar Complete Care service contract

Kalmar has announced a 3-year service contract with Port of Halmstad (Hallands Hamnar Halmstad AB) in Sweden. Under the agreement, Kalmar will continue delivering comprehensive maintenance through its Kalmar Complete Care service contract, ensuring maximum uptime, productivity, and operational safety across the port’s cargo-handling equipment fleet. The contract was booked in Kalmar’s Q3 2026 order intake.

Hallands Hamnar Port of Halmstad is one of Sweden’s 10 largest seaports and a critical full-service logistics hub strategically positioned along the Kattegat coast. It operates across specialized terminals and a mixed fleet of material handling equipment tailored to support its diverse operations of handling containers, RoRo, steel, scrap metal, and forest products.

Jens Madsen, Service manager, Port of Halmstad: “Kalmar has supported our terminal operations for many years. Renewing our Kalmar Complete Care contract helps us maintain reliable and efficient operations, keep cargo moving smoothly and deliver the level of service our customers expect.” 

Anna Jern-Houttu, VP Service Solutions: “We’re delighted to continue our long-standing collaboration with the Port of Halmstad. Our local service teams work closely with the port every day to ensure their fleet operates at peak efficiency. Renewing this Complete Care service contract reflects the deep trust we’ve built together, and we’re committed to supporting Port of Halmstad’s ongoing goals for productivity, safety, and operational excellence.” 

Through this service partnership, Kalmar continues to execute its strategy of growing services, supporting customers with deep-rooted expertise, and making every move count across heavy logistics networks worldwide.

Further information for the press:

Anna Jern-Houttu, VP Service Solutions, anna.jern-houttu@kalmarglobal.com

Jenni Laukkonen, Director Marketing and Communications Services, tel. +358408322331, jenni.laukkonen@kalmarglobal.com 

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com 

Attachment

• Kalmar and Port of Halmstad continue partnership with the signing of a Kalmar Complete Care service contract

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 7 OCTOBER 2026 AT 18.00 P.M. EEST, MAJOR SHAREHOLDER ANNOUNCEMENT

Notification under Chapter 9, Section 10 of the Securities Market Act: Holdings of Etelä-Karjalan Säästöpankkisäätiö in Oma Savings Bank Plc has decreased below 10%

On 7 October 2026, Oma Savings Bank Plc (OmaSp) received a notification under Chapter 9, Section 5 of the Securities Market Act (SMA) from Etelä-Karjalan Säästöpankkisäätiö (business ID 2231936-2), according to which Etelä-Karjalan Säästöpankkisäätiö’s holding and voting rights in OmaSp decreased below 10% on 7 October 2026.

According to the announcement, Etelä-Karjalan Säästöpankkisäätiö sr owns 0 OmaSp shares, corresponding to 0 percent of OmaSp’s shares and votes.

OmaSp has one class of shares in which each share has one vote. The total number of shares is 33,356,729.

The holding of Etelä-Karjalan Säästöpankkisäätiö sr according to the announcement:

	% of shares and voting rights (A)	% of shares and voting rights through financial instruments (B)	Total of both in % (A+B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0	0	0	33 356 729
Positions of previous notification (if threshold crossed)	27,28		27,28

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights:

Class/type of shares	Number of shares and voting rights		% of shares and voting rights
ISIN code	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000306733	0	0	0	0
A total	0		0

Oma Savings Bank Plc

Additional information:

Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi

Distribution:

Nasdaq Helsinki Ltd
Major media
www.omasp.fi

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki. Oma Savings Bank is a part of S-Bank Group.

Growth into Kern, Kings and Tulare counties and an expanded provider network give California Medicare beneficiaries more local care options

ORANGE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) — Alignment Health Plan, an award-winning Medicare Advantage plan from Alignment Health, today announced it will expand into Kern, Kings and Tulare counties and add Hoag and Astrana Health to its California provider network for 2027. Beginning Jan. 1, Alignment Health Plan will serve 25 California counties that are home to more than 6.3 million Medicare beneficiaries, according to Centers for Medicare & Medicaid Services (CMS) data¹. 

Alignment’s 2027 California portfolio features 46 Medicare Advantage plans supported by an expansive network of trusted provider partners, giving people with Medicare access to coordinated, high-quality care close to home. New members can choose from a range of plans with premiums as low as $0, including specialized plans designed for people living with diabetes or certain heart conditions, subject to eligibility and plan availability. Members must continue to pay their Medicare Part B premium.

“California is our home, and we remain focused on showing up where we can make the greatest difference for people with Medicare,” said Dawn Maroney, president of Alignment Health and CEO of Alignment Health Plan. “As we expand into the Central Valley and strengthen relationships with trusted provider partners like Hoag and Astrana Health, we’re making it easier for seniors to access high-quality, coordinated care close to home, with the personalized support they deserve.”

More Provider Choice Across Southern California 

• Hoag in Orange County. Beginning Jan. 1, eligible Alignment Health Plan members in Orange County will have in-network access to Hoag through select plans, including the new $0-premium Alignment Health Platinum Preferred (HMO) plan. Hoag’s network includes 1,800 physicians, two acute-care hospitals and a broad network of urgent care and outpatient facilities. 
• Astrana Health across Southern California. Alignment Health Plan is adding Astrana Health’s network of 2,000 primary care providers and 5,000 specialty care providers in Los Angeles, Orange, Riverside and San Bernardino counties. Astrana-affiliated medical groups include community-based, multilingual providers serving the region’s diverse population. 

Plan Choices Designed Around Members

Alignment’s 2027 California portfolio includes Platinum and My Choice HMO options, as well as Smart HMO plans in select counties that offer members a monthly rebate toward their Medicare Part B premium. Additional plan options are available for people living with diabetes, heart conditions or other qualifying health needs who meet applicable eligibility requirements, and for those eligible for both Medicare and Medi-Cal. In Los Angeles and Orange counties, Central Health Harmony (HMO) offers access to culturally-connected care with Chinese-, Korean- and Vietnamese-speaking providers and member support.

All members have access to Alignment’s 24/7 concierge team for personalized support, including help understanding benefits, finding the right doctor and coordinating care. Depending on the plan, members may also enjoy benefits such as $0 copays on many commonly prescribed medications, over-the-counter and grocery allowances, fitness programs and in-home support.²

Medicare’s Annual Enrollment Period runs Oct. 15 through Dec. 7, with coverage taking effect Jan. 1, 2027. To learn more about Alignment Health’s 2027 Medicare Advantage plans in California, visit alignmenthealthplan.com or call 1-888-979-2247.³

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Media Contact:
Jerry Slowey
publicrelations@ahcusa.com

Y0141_27446EN_M

_____________________________
¹ Centers for Medicare & Medicaid Services Medicare Advantage/Part D Contract and Enrollment Data, September 2026 MA State/County Penetration
² Special supplemental benefits for the chronically ill (SSBCI)-qualifying chronic conditions include congestive heart failure (CHF), dementia, diabetes, and stroke. Other chronic conditions may apply. Medical records will be used to establish the member qualification. The benefits mentioned are a part of a special supplemental program for the chronically ill. Not all members qualify because other eligibility and coverage criteria also apply.
³ Alignment Health Plan is an HMO, HMO POS, HMO C-SNP, HMO D-SNP and PPO plan with a Medicare contract and a contract with the California, Nevada, North Carolina and Texas Medicaid programs. Enrollment in Alignment Health Plan depends on contract renewal. The benefit information provided is a summary, not a complete description of benefits. For more information, contact the plan. Call 1-888-979-2247 (TTY: 711), 8 a.m. to 8 p.m. Monday through Friday, for more information. Other providers are available in our network.

Company to Highlight Passive and Semiconductor Technologies and Reference Designs for Battery Management, Protection, and Power Conversion

MALVERN, Pa., Oct. 07, 2026 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH) today announced that the company will showcase its latest passive component technologies, semiconductors, and reference designs at The Battery Show North America 2026, taking place October 12–15 in Detroit (Booth 4807). At the event, Vishay will highlight solutions that address key design challenges in battery management, protection, and high voltage power conversion for electric vehicles and energy storage systems.

At The Battery Show North America 2026, Vishay will present:

• Passives:
  • AEC-Q200 qualified NTC thermistor solutions that enable fast, accurate, and stable temperature monitoring in battery cells, modules, and packs, supporting thermal runaway mitigation, charging optimization, and extended battery life
  • UL-recognized resettable overcurrent protection solutions that help safeguard battery packs, charging circuits, and auxiliary power networks from fault conditions for increased system safety and reliability
• Semiconductors:
  • Gen 5 TrenchFET^® MOSFET technology engineered to reduce figure of merit (FOM) for increased efficiency in power conversion applications
  • P-channel MOSFET solutions and Gen 3 MaxSiC silicon carbide (SiC) trench MOSFETs for high voltage power conversion
  • Latest-generation SiC Schottky diodes, FRED Hyperfast rectifiers, and TMBS^® technologies designed to reduce power losses and provide high efficiency switching and rectification
  • Automotive qualified optoelectronic solutions for battery systems, including isolated MOSFET drivers, optical cell to cell balancing, and photo relays for leakage detection at load voltages up to 1500 V. The portfolio also includes a wide body phototransistor optocoupler with 11 mm creepage and a high speed optocoupler supporting CAN, LIN, SPI, and I2C communication up to 1 MBd.
• Reference Designs:
  • Active discharge circuit reference designs providing reliable solutions for discharging stored energy in 400 V and 800 V DC-Link capacitors, helping automotive systems reach safe voltage levels within required timeframes
  • An intelligent battery shunt sensor reference design that enables high bandwidth, accurate current and voltage measurements across a wide temperature range without temperature compensation

At Booth 4807, Vishay experts will also be available to discuss customer design challenges across battery management systems, onboard chargers, DC/DC converters, traction inverters, and high voltage power architectures. Attendees are invited to bring their questions, schematics, requirements, and design goals to explore system-level solutions and design tradeoffs with Vishay’s technical experts. Further information, including a meeting request form, is available here.

Vishay manufactures one of the world’s largest portfolios of discrete semiconductors and passive electronic components that are essential to innovative designs in the automotive, industrial, computing, consumer, telecommunications, military, aerospace, and medical markets. Serving customers worldwide, Vishay is The DNA of tech.^® Vishay Intertechnology, Inc. is a Fortune 1000 Company listed on the NYSE (VSH). More on Vishay at www.Vishay.com.

The DNA of tech^® is a registered trademark of Vishay Intertechnology, Inc.

Vishay on Facebook: http://www.facebook.com/VishayIntertechnology
Vishay Twitter feed: http://twitter.com/vishayindust

Link to DNA of Tech image:
https://www.flickr.com/photos/205032290@N04/albums/72177720336017758

For more information please contact:
Vishay Intertechnology
Peter Henrici, +1 408 567-8400
peter.henrici@vishay.com
or
Redpines
Bob Decker, +1 415 409-0233
bob.decker@redpinesgroup.com

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — Partners Value Split Corp. (the “Company”) announced today that it has entered into an agreement to sell 5,000,000 Class AA Preferred Shares, Series 18 (the “Series 18 Preferred Shares”) to a syndicate of underwriters led by Scotiabank, BMO Capital Markets, CIBC Capital Markets, RBC Capital Markets and TD Securities Inc. on a bought deal basis.

The Series 18 Preferred Shares will be issued at a price of $25.00 per share, for gross proceeds of $125,000,000. The Series 18 Preferred Shares will carry a fixed coupon of 5.30% and will have a final maturity of September 29, 2033. The Series 18 Preferred Shares have a provisional rating of Pfd-2 from DBRS Limited. The net proceeds of the offering will be used by the Company to make distributions to the holder of the Company’s capital shares.

The Company has granted the underwriters an option, exercisable in whole or part prior to closing, to purchase up to an additional 1,000,000 Series 18 Preferred Shares at the same offering price, which, if exercised in full, would increase the gross offering size to $150,000,000. Closing of the offering is expected to occur on or about October 15, 2026.

The Company owns a portfolio consisting of approximately 179 million Class A Limited Voting Shares of Brookfield Corporation and approximately 25 million Class A Limited Voting Shares of Brookfield Asset Management Ltd. (collectively, the “Brookfield Securities”), which are expected to yield quarterly dividends that are sufficient to fund quarterly fixed cumulative preferential dividends for the holders of the Company’s preferred shares and to enable the holders of the Company’s capital shares to participate in any capital appreciation of the Brookfield Securities.

Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals around the world. Brookfield Corporation has three core businesses: Asset Management, Wealth Solutions, and Brookfield Corporation’s Operating Businesses which are in infrastructure, energy, private equity and real estate. Brookfield Corporation is listed on the New York Stock Exchange and Toronto Stock Exchange under the symbol BN.

Brookfield Asset Management Ltd. (“BAM”) is a leading global alternative asset manager, headquartered in New York, with over US$1 trillion of assets under management across infrastructure, energy, private equity, real estate, and credit. BAM invests client capital for the long-term with a focus on real assets and essential service businesses that form the backbone of the global economy. BAM offers a range of alternative investment products to investors around the world — including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies and private wealth investors. BAM draws on Brookfield’s heritage as an owner and operator to invest for value and generate strong returns for its clients, across economic cycles. BAM is listed on the New York Stock Exchange and Toronto Stock Exchange under the symbol BAM.

Onaiza Ahmed, Chief Financial Officer, will be available at (416) 363-9491 to answer any questions regarding the offering.

This news release contains “forward-looking information” within the meaning of Canadian provincial securities laws and regulations. The words “expected”, “will”, “agreed” and “enable” and other expressions which are predictions of or indicate future events, trends or prospects and which do not relate to historical matters or identify forward-looking information. Forward-looking information in this news release includes statements with regard to the provisional rating on the Series 18 Preferred Shares, which is not a final rating, the use of proceeds of the offering and quarterly dividends from the Company’s portfolio of Brookfield Securities which are expected to fund quarterly fixed cumulative preferential dividends for holders of the Company’s preferred shares and to enable holders of its capital shares to participate in any capital appreciation of the Brookfield Securities. Although the Company believes that the anticipated future results or achievements expressed or implied by the forward-looking information and statements are based upon reasonable assumptions and expectations, the reader should not place undue reliance on the forward-looking information and statements because they involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from anticipated future results, performance or achievement expressed or implied by such forward-looking information and statements. Factors that could cause actual results to differ materially from those contemplated or implied by the forward-looking information and statements include: the behaviour of financial markets, including fluctuations in interest and exchange rates, availability of equity and debt financing and other risks and factors detailed from time to time in the Company’s other documents filed with the Canadian securities regulators. We caution that the foregoing list of important factors that may affect future results is not exhaustive. When relying on our forward-looking information to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as may be required by law, the Company undertakes no obligation to publicly update or revise any forward-looking information or statements, whether written or oral, that may be as a result of new information, future events or otherwise. Reference should be made to the Company’s short form base shelf prospectus dated February 20, 2026 for a description of the major risk factors.

DASSAULT AVIATION

French corporation (société anonyme) with a share capital of 61,754,887.20 euros
Headquarters: 78, quai Marcel Dassault
92210 SAINT-CLOUD
712 042 456 RCS Nanterre

Information concerning the total number of voting rights and shares as per article L. 233-8 II of the French Commercial Code (Code de commerce) and article 223-16 of the General Regulations (Règlement Général) of the French Market Authority (Autorité des Marchés Financiers)

Date	Total number of shares	Total number of voting rights
09/30/2026	77,193,609	Theoretical voting rights: 129,407,481 Exercisable voting rights: 128,910,682

Attachment

• Total number of shares and voting rights – 30 09 26

Oslo, Norway (7 October 2026) – TGS, a leading global provider of energy data and intelligence will release its Q3 2026 results at approximately 07:00 a.m. CEST on 22 October.

CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 a.m. CEST on 22 October. The presentation will be webcasted live.

Webcast access and registration are available by copying and pasting the link below into your browser, or use the link on the front page of www.tgs.com:
https://qcnl.tv/p/F9pp7ArbItpZ5nPyrrIErw

The Q3 2026 earnings release and presentation will be available on www.tgs.com and www.newsweb.no.

For more information, visit TGS.com (http://www.tgs.com) or contact:

Bård Stenberg, VP IR & Business Intelligence
Mobile: +47 992 45 235
E-mail: investor@tgs.com

About TGS
TGS provides advanced data and intelligence to companies active in the energy sector. With leading-edge technology and solutions spanning the entire energy value chain, TGS offers a comprehensive range of insights to help clients make better decisions. Our broad range of products and advanced data technologies, coupled with a global, extensive and diverse energy data library, make TGS a trusted partner in supporting the exploration and production of energy resources worldwide. For further information, please visit www.tgs.com (https://www.tgs.com/).

Third Quarter Top-Line Increases 106% Sequentially, Reflecting Expanded Enterprise Scale and Combined Go-To-Market Execution including ConnectAndSell

SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: PARA) (d/b/a “Parabolic” or the “Company”), a leading AI-powered agentic applications technology company, today announced selected preliminary revenue for the third quarter ended September 30, 2026 to provide visibility into the operational progress of its scaled business platform.

Preliminary Third Quarter 2026 Revenue Highlights

• Total Revenue: Expected to be approximately $4.7 million for the third quarter of 2026.
• Sequential Growth: Represents an increase of 106% compared to $2.3 million in the second quarter of 2026.
• Year-Over-Year Growth: Represents an increase of 65% compared to $2.8 million in the third quarter of 2025.

Consolidated third-quarter revenue reflects top-line expansion from the ConnectAndSell platform integration, marking the first quarter of financial contributions from this business unit.

“Our preliminary third-quarter revenue demonstrates the clear operational scale we achieved following the close of our ConnectAndSell transaction. Reaching $4.7 million in top-line revenue for the quarter is a significant milestone and record high quarterly revenue for Parabolic,” said Joe Davy, Founder and CEO of Parabolic.

“Over the past three months, our team has focused heavily on executing a smooth post-merger integration, ensuring that our newly acquired enterprise accounts continue to receive premier service while beginning to migrate infrastructure to our core platform. This expanded top-line scale, when paired with the $9.3 million cost savings measure we recently announced, strengthens our financial footing and supports our progress toward profitability.”

Parabolic will report full third quarter 2026 financial results on Monday, November 16, 2026, after market close. The preliminary revenue figure above is unaudited, is based on information currently available to management, and is subject to completion of the Company’s quarter-end closing procedures. Actual results may differ from this estimate and will be reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

About Parabolic

Parabolic builds agentic applications that power the future of business. We believe that the future of enterprise software will be agentic applications that are net-beneficiaries of AI transformation, and we focus on building, acquiring, and investing in those and related businesses. We have over 150,000 customers including Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, and Fitch Group. Learn more at www.parabolic.io. For investors, please visit ir.banzai.io.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding Banzai International, Inc.’s (the “Company’s”): future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to the Company’s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for retaining existing or acquiring new customers, increasing revenue and executing growth initiatives; and product areas of focus and additional products that may be sold in the future. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which the Company operates, customer demand, the financial markets, economic, business and regulatory and other factors, such as the Company’s ability to execute on its strategy. More detailed information about risk factors can be found in the Company’s Annual Report on Form 10-K and the Company’s Quarterly Reports on Form 10-Q under the heading “Risk Factors,” and in other reports filed by the Company, including reports on Form 8-K. The Company does not undertake any duty to update forward-looking statements after the date of this press release.

Investor Relations
Dean Ditto
Chief Financial Officer
206 414-1777
ir.banzai.io

Media
Paul Witkowski
Senior Director Financial Reporting
media@banzai.io